Top news of the week: 08.09.2020.

#biospace #biotechnology #lifesciences #pharmaceuticals #COVID19 #coronavirus #treatment #COVID #vaccine #pandemic

Companies And Industries

On Sep 2, 2020
@biospace shared
Biopharma Update on the Novel Coronavirus: September 2 #biospace #lifesciences #biotechnology #pharmaceuticals #COVID-19 #coronavirus #pandemic #COVID19 #treatment #vaccine https://t.co/71De3kCFfM
Open

Biopharma Update on the Novel Coronavirus: September 2

Biopharma Update on the Novel Coronavirus: September 2

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 2, 2020.

On Sep 4, 2020
@biospace shared
Biopharma Update on the Novel Coronavirus: September 4 #biospace #lifesciences #biotechnology #pharmaceuticals #COVID-19 #coronavirus #pandemic #COVID19 #treatment #vaccine https://t.co/nVPTj6IRku
Open

Biopharma Update on the Novel Coronavirus: September 4

Biopharma Update on the Novel Coronavirus: September 4

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 4, 2020.

On Sep 4, 2020
@matthewherper shared
China's I-Mab gets boost from AbbVie to develop cancer therapy https://t.co/vzl9lpsFlM
Open

‘The race is on’: China’s I-Mab gets boost from AbbVie to develop a new cancer immunotherapy

‘The race is on’: China’s I-Mab gets boost from AbbVie to develop a new cancer immunotherapy

Shanghai-based I-Mab has signed a global collaboration deal with U.S. drug maker AbbVie to develop lemzoparlimab, I-Mab’s homegrown cancer immunotherapy.

On Sep 2, 2020
@FierceBiotech shared
Namouni will lead the company’s efforts to develop Ayvakit and pralsetinib, ramp up its preclinical pipeline and “prioritize new targets and technologies,” for its future work https://t.co/oEgHp8mAQd
Open

BMS oncology chief Namouni lands at Blueprint Medicines to lead R&D

BMS oncology chief Namouni lands at Blueprint Medicines to lead R&D

As Blueprint Medicines preps for the U.S. and EU approvals of its RET inhibitor, the company is bringing its research and clinical development work under one roof and putting Bristol Myers ...

On Sep 4, 2020
@BioWorld shared
Records already set, but the money keeps rolling in for biopharma https://t.co/ivtCXrjYU6
Open

Records already set, but the money keeps rolling in for biopharma

Records already set, but the money keeps rolling in for biopharma

The biopharma industry has raised a total of about $88 billion so far in 2020, the most ever for a single year, with four months to go. It hit the record in July when it surpassed the $68.4 ...

On Sep 1, 2020
@matthewherper shared
Fact check: Dr. Fauci was not the first CEO and other false claims about biotech company Moderna. Don’t assume things are true. https://t.co/VG09jhfRuH
Open

Fact check: Dr. Fauci was not the first CEO and other false claims about biotech company Moderna

Fact check: Dr. Fauci was not the first CEO and other false claims about biotech company Moderna

Tens of thousands of users are sharing a series of claims that link Dr. Anthony Fauci, Bill Gates, George Soros and Jeffrey Epstein to Moderna, one of the leading contenders in the race to ...

On Sep 2, 2020
@biospace shared
Celyad's High Hopes for a Path Forward in Cancer Immunotherapy with CYAD-211 #biospace #lifesciences #biotechnology #pharmaceuticals #cancer https://t.co/8ssbZ1VMtP
Open

Celyad's High Hopes for a Path Forward in Cancer Immunotherapy with CYAD-211

Celyad's High Hopes for a Path Forward in Cancer Immunotherapy with CYAD-211

Celyad Oncology is at the forefront of cutting-edge immunotherapy and is hopeful of providing a new way forward for patients with relapsed/refractory multiple myeloma.

On Sep 1, 2020
@LabRoots shared
The PAWS FOR A CURE Research Symposium, Sept 29-30, will highlight “Translational Potential Of Comparative Approaches To Accelerate Drug Development In Shared Childhood & Canine Cancers”. Register for free: https://t.co/2j2Bk3Cqbr #pawsFORacure2020 @CNKFoundation https://t.co/xrZWJmp5XP
Open

2nd Annual PAWS FOR A CURE Research Symposium

2nd Annual PAWS FOR A CURE Research Symposium

2nd ANNUAL PAWS FOR A CURE VIRTUAL EVENT RESEARCH SYMPOSIUM Translational Potential Of Comparative Approaches To Accelerate Drug Development In Shared Childhood & Canine Cancers We are